EDAP TMS (EDAP)
(Delayed Data from NSDQ)
$4.89 USD
+0.06 (1.18%)
Updated Jul 30, 2024 12:34 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EDAP 4.89 +0.06(1.18%)
Will EDAP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EDAP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EDAP
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
New Strong Sell Stocks for October 17th
EDAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
SentinelOne (S) to Report Q4 Earnings: What's in the Cards?
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
Other News for EDAP
Lake Street Keeps Their Buy Rating on EDAP TMS (EDAP)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)
Buy Rating on EDAP TMS Maintained Despite Mixed Phase 3 Results, Highlighting Potential of HIFU for Endometriosis
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
EDAP Reports Promising HIFU Therapy Study Results